I am a radiation oncologist who specializes in the treatment of prostate cancer, bladder cancer, and testicular cancer. My particular expertise is managing the early detection and treatment of prostate cancer. Prostate cancers present and progress in different ways. While some prostate cancers pose little threat to health, others may grow aggressively. In many cases, radiotherapy or surgery can be curative. We are actively studying new ways to preserve bowel, urinary and sexual function after radiotherapy and to improve quality of life for patients after treatment. For example, to improve outcomes while minimizing the side effects of radiotherapy, we use sophisticated technologies like proton beam therapy and image-guided, intensity-modulated radiotherapy.
Justin E. Bekelman, M.D., is Associate Professor in the Department of Radiation Oncology (Primary) and the Department of Medical Ethics and Health Policy (Secondary) at the Perelman School of Medicine, Associate Scholar in the Center for Clinical Epidemiology and Biostatistics, Faculty in the Center for Health Incentives and Behavioral Economics, and Senior Fellow at the Leonard Davis Institute for Health Economics at the University of Pennsylvania. Dr. Bekelman leads research programs in cancer comparative effectiveness and delivery system and payment reform, integrating methods from the fields of epidemiology, clinical trials, health economics and public policy. In his current comparative effectiveness work, Dr. Bekelman leads the 22 institution Radiation Comparative Effectiveness Consortium (RADCOMP) pragmatic randomized clinical trial comparing proton to photon radiation therapy for breast cancer and co-leads the PARTIQoL randomized clinical trial comparing proton to intensity-modulated radiation therapy (IMRT) for prostate cancer (the first randomized trial of proton and photon delivery in the modern treatment era). In his delivery system and payment reform work, Dr. Bekelman leads a series of quasi-experimental studies to evaluate the impact of narrow networks and reimbursement reforms on the use, costs, quality and outcomes of cancer treatments. Dr. Bekelman's research has appeared in scientific journals such as the Journal of the American Medical Association and the Journal of Clinical Oncology and has been featured in the mainstream media, including the New York Times, the Wall Street Journal, National Public Radio, and news outlets in Canada and Europe. He has received research funding from the National Cancer Institute, the Patient-Centered Outcomes Research Institute, the American Cancer Society, and philanthropic sources.
Dr. Bekelman completed his undergraduate studies at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.
Li J, Handorf E, Bekelman J, and Mitra N: Propensity score and doubly robust methods for estimating the effect of treatment on censored cost. Statistics in Medicine 2016. In press.
Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Herr HW, Lerner SP, Guzzo TJ, Malkowicz SB, Christodouleas JP: Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. Int J Radiat Oncol Biol Phys 2016. In press.
Sharma S, Bekelman JE, Lin A, Lukens JN, Roman BA, Mitra N, Swisher-McClure S: Clinical Impact of Prolonged Diagnosis to Treatment Interval Among Patients with Oropharyngeal Squamous Cell Carcinoma. Oral Oncology 2016. In press.
Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ: Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. JAMA 315(3): 272-283, 2016.
Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, Armstrong K: Effectiveness of Androgen Deprivation Therapy and Radiotherapy for Older Men with Locally Advanced Prostate Cancer. Journal of Clinical Oncology 33(7): 716-22, 2015.
Kirk ML, Tang S, Zhai H, Vapiwala N, Deville C, James P, Bekelman JE, Christodouleas JP, Tochner Z, and Both S: Comparison of prostate proton treatment planning technique, interfraction robustness, and analysis of single-field treatment feasibility. Practical Radiation Oncology 5(2): 99-105, 2015.
Suneja G, Boyer M, Yehia BR, Shiels MS, Engels EA, Bekelman JE, Long JA: Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists. J Oncol Pract 11: e380-7, 2015.
Fang P, Mick R, Deville C, Both S, Bekelman J, Christodouleas J, Guzzo T, Tochner Z, Hahn S, Vapiwala N: A Case-Matched Study of Toxicity Outcomes after Proton Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer. Cancer 121(7): 1118-27, 2015.
Corcoran AT, Handorf E, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A, Smaldone MC: Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int 115(2): 230-7, 2015.
Berrington A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE: Risk of second cancers according to radiotherapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys 91(2): 295-302, 2015.
back to top
Last updated: 05/29/2016
The Trustees of the University of Pennsylvania